BioCentury
ARTICLE | Strategy

Risky business

How Amgen is approaching Repatha access post FOURIER data

March 25, 2017 1:51 AM UTC

Amgen Inc.’s proposal to increase access to cholesterol drug Repatha evolocumab will hinge on increasing medication adherence rates. In addition to continuing its existing adherence programs that use electronic alerts, the biotech hopes to take a page out of the playbooks of PBMs that have developed programs for HCV.

Data presented at the American College of Cardiology provided grist for Amgen to persuade payers to increase access to Repatha, and also put a fine point on the challenges it will face in doing so...

BCIQ Company Profiles

Amgen Inc.

BCIQ Target Profiles

PCSK9